Diabetes treatment is constantly advancing, with new therapeutic options developing to improve patient outcomes. Recent studies have focused on GLP-1 and GIP receptor agonists, a category of drugs that mimic the actions of naturally occurring hormones involved in bloodlevel regulation. These novel agents demonstrate substantial efficacy in managing

In the ever-evolving landscape of diabetes management, a fresh approach is emerging that focuses on directly targeting glucose levels. This innovative strategy involves leveraging the power of two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP have shown promising results in cont